Post by Syntegon

Antibody-Drug Conjugates (ADCs) have moved from niche to mainstream, but their high potency, lyophilized formats and tightening timelines mean precise vial filling, maximum yield and operator protection are non‑negotiable.​ With faster, safer, integrated vial filling, higher yield and strong local support, we co-create your ADC line, so it can go to market sooner and with less regulatory and operational risk.​ Read more about our recent ADC project in China on the link below: https://lnkd.in/eSmgbVP5 #COCREATE #COSUCCEED #Syntegon #LifecyclePartner